Increasing Diagnosis and Treatment of Overweight and Obese Pediatric Patients

Emily Laura Young1

  • 1Medical University of South Carolina, Charleston, SC, USA emily.l.young.cpnp@gmail.com.

Clinical Pediatrics
|April 17, 2015
PubMed

Insights

Implementing an electronic health record (EHR) template and staff education significantly improved the diagnosis and treatment rates for overweight and obese children, enhancing pediatric obesity management.

Area of Science:

  • Pediatric Endocrinology
  • Health Informatics
  • Public Health

Background:

  • Childhood obesity is a growing public health concern.
  • Effective clinical strategies are needed to improve diagnosis and management.
  • Electronic Health Records (EHRs) offer potential for systematic interventions.

Purpose of the Study:

  • To evaluate the impact of a guideline-based EHR template and staff education on diagnosing and treating overweight and obese children.
  • To assess improvements in the identification and management of pediatric obesity.

Main Methods:

  • A pediatric obesity evidence-based practice guideline was integrated into an EHR minitemplate.
  • Staff received education on current obesity guidelines.
  • The template was applied to EHR encounters for patients with body mass index (BMI) above the 85th percentile.

Main Results:

  • Diagnosis rates for overweight/obesity increased from 52% to 75% post-intervention.
  • Treatment rates for diagnosed patients rose from 86% to 96%.
  • The study reviewed 9701 patient charts over six months.

Conclusions:

  • EHR customization and targeted staff education effectively enhanced the diagnosis and treatment of pediatric overweight and obesity.
  • This approach demonstrates a successful method for improving clinical care for pediatric obesity.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
349
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
413
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
306
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
886
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391